Jeffrey Allerton, MD
Hematology & Oncology · Cooperstown, NYNPI 1205886181
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $66,000 of the $68,969 with a category attached, or 95.7%. Stemline Therapeutics Inc. accounts for 95.7% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2020 at $26,555 and has fallen 97.8% since, to $593 in 2025. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $599.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stemline Therapeutics Inc.$66K
- Novartis$288
- Astellas Pharma US Inc$287
- Seagen Inc.$221
- Pfizer$207
- E.r. Squibb & Sons, L.L.C.$172
- plus $2K from 30 others
Across 2 payments — averaging $1294.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novocure Inc.$3K
- E.r. Squibb & Sons, L.L.C.$89
What the payments were for
- Consulting fees$66,00096%
- Food & beverage$2,1963%
- Education$7731%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stemline Therapeutics Inc. | 10 | $66,000 |
| Novartis | 8 | $288 |
| Astellas Pharma US Inc | 4 | $287 |
| Seagen Inc. | 4 | $221 |
| Pfizer | 11 | $207 |
| E.r. Squibb & Sons, L.L.C. | 4 | $172 |
| Regeneron Healthcare Solutions, Inc. | 7 | $171 |
| Bristol Myers Squibb | 9 | $165 |
| Merck | 9 | $163 |
| Sanofi | 3 | $143 |
| AVEO Pharmaceuticals, Inc. | 2 | $122 |
| Incyte Corporation | 2 | $116 |
| Daiichi Sankyo Inc. | 4 | $93 |
| AstraZeneca | 5 | $89 |
| Epizyme, Inc. | 1 | $83 |
| Lilly USA, LLC | 6 | $83 |
| Eisai Inc. | 4 | $75 |
| EMD Serono, Inc. | 2 | $57 |
| Iovance Biotherapeutics, Inc. | 2 | $48 |
| Johnson & Johnson | 2 | $44 |
| Pharmaessentia USA Corporation | 1 | $28 |
| Adaptive Biotechnologies Corporation | 1 | $28 |
| Amgen | 1 | $26 |
| Boehringer Ingelheim | 1 | $25 |
| Bayer | 1 | $25 |
| Exelixis Inc. | 1 | $24 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Novocure Inc. | 1 | $22 |
| Beigene USA, Inc. | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Gilead | 1 | $20 |
| Tersera Therapeutics LLC | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Servier Pharmaceuticals LLC | 1 | $16 |
| Morphosys, US Inc. | 1 | $14 |
| Array Biopharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$68,969 in reported general payments places this provider in the 90th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 23 | $91,453 |
| ValacyclovirValacyclovir Hcl | 19 | $725 |
| Anastrozole | 13 | $217 |
| Letrozole | 16 | $185 |
| Prochlorperazine Maleate | 12 | $156 |
| Prednisone | 16 | $121 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Cooperstown
- Anush PatelCooperstown$563K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.